Inclusion Criteria:

          -  Advanced-stage solid tumor (metastatic or locally advanced and unresectable) with
             histologically confirmed diagnosis of CRC, NSCLC, GC, RCC, or HCC

          -  Measurable lesion(s) according to RECIST 1.1 criteria

          -  Performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.

          -  Ability to swallow capsules

          -  Received last chemotherapy, biologic, or investigational therapy at least 4 weeks
             prior to first dosing of study treatment

          -  Has received or is intolerant to all standard of care treatment options with known
             clinical benefit

          -  Life expectancy of more than 3 months

          -  Adequate hematological, hepatic and renal function

          -  For women of childbearing potential, a negative serum pregnancy test performed within
             7 days prior to start of treatment

        Exclusion Criteria:

          -  Received treatment within the last 28 days with a drug that has not received
             regulatory approval for any indication at the time of study entry

          -  Major surgery within the last 28 days prior to the first dose of investigational drug

          -  Prior radiation therapy within 14 days prior to study Cycle 1 Day 1 and/or persistence
             of radiation-related adverse effects.

          -  Concurrent treatment with any anticancer agent

          -  Currently taking either strong CYP inhibitors or inducers

          -  Known brain metastases, uncontrolled seizure disorder, or active neurologic disease

          -  Significant cardiovascular impairment

          -  Pregnant or nursing

          -  Known HIV infection, active hepatitis C and/or hepatitis B infection

          -  Known bleeding disorder or coagulopathy

          -  Active drug or alcohol abuse or history of alcohol or drug abuse during the last two
             years.

          -  Diagnosis of osteoporosis at the time of the screening

          -  Any history of retinal pathology including diabetic retinopathy, macular degeneration,
             or other retinal degenerative disease